diabetes
-
Cipla launches Cippoint, a point-of-care device for NCDs, infectious diseases
Cippoint, an immunofluorescence-based quantitative analyser, will allow healthcare professionals to get test results in three to 15 minutes Cipla announced…
Read More » -
Cytecare Hospitals opens diabetes clinic in Bengaluru
Specialist consultation is also included in the package till March 31, 2023 Cytecare Hospitals has started a diabetes screening clinic…
Read More » -
Younger people seeking solutions for diabetes management: Fitterfly report
Releases year-end report called Reimagining Diabetes Care Report 2022 Fitterfly released its year-end report called Reimagining Diabetes Care Report 2022…
Read More » -
Glenmark launches Triple FDC of Teneligliptin + Pioglitazone + Metformin diabetes drug
The novel triple FDC will help improve glycemic control among adults with High HbA1c and high insulin resistance, those whose…
Read More » -
Digital Therapeutics is game changer in chronic disease mgmt: Phable study
The study showcases conclusive results for Type 2 Diabetes and Hypertension Phable unveiled insights from their recent clinical studies conducted…
Read More » -
One out of three people with uncontrolled diabetes develop diabetic retinopathy: Study
Dr Saurabh Choudhry, CEO, ICARE Eye Hospital, Noida 63 per cent of Indians lack awareness that diabetes can damage eye health…
Read More » -
Lilly to rollout of Tempo personalised diabetes management platform
The platform consists of three key components – the Tempo Smart Button; a compatible app, TempoSmart; and a prefilled insulin…
Read More » -
Glenmark launches Teneligliptin + Dapagliflozin Fixed-Dose Combination for adults with Type 2 diabetes
The company aims to improve glycemic control in adult patients with uncontrolled type‐2 diabetes Glenmark Pharmaceuticals became the first to…
Read More » -
SRL Diagnostics launches Fatty Liver Index
The index is an algorithm-based testing for fatty liver disease SRL Diagnostics has launched ‘Fatty Liver Index’; a first-line diagnostic…
Read More » -
Novo Nordisk India launches GLP-1 RA, Oral Semaglutide, to treat diabetes
Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), indicated for the management of type 2 diabetes has been developed in an…
Read More »
